Imanova drives innovation in imaging - announcing winners of its IMPETus 2015 Pilot Grants

London, February 2016: Imanova has announced the winners of its IMPETus 2015 grant programme. Open to academic researchers across the UK, the programme aims to expand PET imaging applications by encouraging new researchers in new areas of science to generate early data to support full grant applications. The IMPETus programme has already led to successful full grant applications in Huntington’s disease and Schizoprenia, with over £2 million in grant funding secured. IMPETus 2015 received high quality applications across a wide range of novel PET applications, including fibrosis, cell tracking, epilepsy, cognition, obesity, oncology and glial activation. The Imanova supported projects in IMPETus 2015 are: • Development of a novel dopamine receptor genetic reporter for CAR T-cell tracking with PET Mark Lythgoe and Martin Pule (University College London) • Sensitivity of the serotonin 2A agonist PET radiotracer, 11C-CIMBI-36, to serotonin release David Erritzoe (Imperial College London) • Mu-opioid binding potential in chronic fatigue syndrome Julius Bourke (Queen Mary University London) • Imidazoline-2 Binding Site as a novel target in Huntington’s disease: An [11C]BU99008 Positron Emission Tomography study Marios Politis (King’s college London) The winners were chosen on the basis of the uniqueness of their scientific proposition and its ability to expand innovation in imaging. Professor Roger Gunn, CSO of Imanova commented “We have been delighted with the quality of the science and breadth of novel PET applications in the 2015 IMPETus submissions. We hope that they will be successful and lead to further expansion of imaging in research” For more information on Imanova Limited and PET imaging, visit www.imanova.co.uk.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.